Novel Therapeutic Strategies for Lung Cancer: Repurposing of FDA-Approved Drugs

Strategic Insights -

Researchers from King Saud University, Riyadh, Saudi Arabia, have identified two FDA-approved compounds, Radotinib and Alectinib, as potential therapeutic agents for lung cancer. By employing computational approaches to repurpose these drugs, the study aimed to overcome the challenges associated with existing MEK inhibitors, such as on-target toxicities and drug resistance. The research suggests that Radotinib and Alectinib exhibit superior binding and conformational stability to the MEK1 enzyme, positioning them as promising repurposed MEK1 inhibitors.

Key Takeaways:

  • The dual specificity mitogen-activated protein kinase kinase 1 (MEK1) is a critical node in the RAS-RAF-MEK-ERK signaling pathway, frequently dysregulated in cancers due to mutations in upstream regulators.
  • Radotinib and Alectinib exhibited superior docking scores (-10.5 and -10.2 kcal/mol) and molecular dynamics simulations revealed stable drug complexes, suggesting robust binding to MEK1's allosteric pocket.
  • Principal component analysis and free energy landscapes corroborated the conformational stability of Radotinib and Alectinib, suggesting them as promising repurposed MEK1 inhibitors.
  • The research concluded that experimental validation is essential to confirm the efficacy and safety of Radotinib and Alectinib in MEK1-linked malignancies.
  • King Saud University researchers employed computational approaches to identify repurposed MEK1 inhibitors through structure-based virtual screening of 3,500 FDA-approved drugs.
  • The study highlights the potential of drug repurposing as a fast and cost-effective alternative for identifying novel therapeutic strategies for lung cancer.

Statistics:

  • 3,500 FDA-approved drugs were screened using computational approaches.
  • Radotinib and Alectinib exhibited docking scores of -10.5 and -10.2 kcal/mol, outperforming the reference MEK1 inhibitor Selumetinib (-7.2 kcal/mol).
  • Molecular dynamics simulations revealed stable drug complexes, with lower root mean square deviation (RMSD) and fluctuations (RMSF) than Selumetinib.
  • Principal component analysis and free energy landscapes were used to corroborate the conformational stability of Radotinib and Alectinib.

Sources:

  • In silico repurposing of FDA-approved drugs against MEK1: structural and dynamic insights into lung cancer therapeutics. Frontiers in Pharmacology, 2025, 16. (Frontiers in Pharmacology - http://journal.frontiersin.org/journal/pharmacology)
  • https://doi-org.sdpl.idm.oclc.org/10.3389/fphar.2025.1619639
  • NewsRx. Reports Outline Lung Cancer Study Findings from King Saud University (In silico repurposing of FDA-approved drugs against MEK1: structural and dynamic insights into lung cancer therapeutics). Cancer Weekly. September 16, 2025; p 889.